TTM
−$47.73M
YoY change
-31.4%
5Y CAGR
—
Peak year (2021)
$124.21M
Cumulative operating income
−$409.74M
Operating Income history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: −$42.44M
Operating Income growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -31.4%
Operating Income history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | −$42.44M | -31.4% | +$19.45M | ||
| 2024 | −$61.88M | +4.4% | −$2.60M | ||
| 2023 | −$59.28M | +6.7% | −$3.73M | ||
| 2022 | −$55.55M | -144.7% | −$179.76M | ||
| 2021 | $124.21M | -252.5% | +$205.64M | ||
| 2020 | −$81.43M | +32.6% | −$20.02M | ||
| 2019 | −$61.41M | +16.0% | −$8.48M | ||
| 2018 | −$52.93M | -18.6% | +$12.08M | ||
| 2017 | −$65.01M | +188.5% | −$42.47M | ||
| 2016 | −$22.54M | +70.8% | −$9.35M | ||
| 2015 | −$13.19M | +2850.8% | −$12.74M | ||
| 2014 | −$447.00K | — | — |
- 2025−$42.44M-31.4%
- 2024−$61.88M+4.4%
- 2023−$59.28M+6.7%
- 2022−$55.55M-144.7%
- 2021$124.21M-252.5%
- 2020−$81.43M+32.6%
- 2019−$61.41M+16.0%
- 2018−$52.93M-18.6%
- 2017−$65.01M+188.5%
- 2016−$22.54M+70.8%
- 2015−$13.19M+2850.8%
- 2014−$447.00K—
Operating Income values are taken from Ovid Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's current operating income (TTM) is −$47.73M. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Ovid Therapeutics (OVID) reported operating income of −$42.44M – plunged 31.4% year-over-year.
Ovid Therapeutics operating income plunged from $124.21M in 2021 to −$42.44M in 2025, a 134.2% drawdown.
2021 marks the peak operating income at $124.21M, with the historical low of −$81.43M recorded in 2020.
Ovid Therapeutics Operating Income by Year
Ovid Therapeutics Operating Income 2025: −$42.44M
In 2025, Ovid Therapeutics reported operating income of −$42.44M, plunged 31.4% below 2024.
Ovid Therapeutics Operating Income 2024: −$61.88M
Ovid Therapeutics operating income in 2024 was −$61.88M, edged up 4.4% from 2023.
Ovid Therapeutics Operating Income 2023: −$59.28M
2023's operating income for Ovid Therapeutics came in at −$59.28M, grew 6.7% from 2022.
Ovid Therapeutics Operating Income 2022: −$55.55M
Ovid Therapeutics posted operating income of −$55.55M in 2022, plunged 144.7% below 2021.
Ovid Therapeutics Operating Income 2021: $124.21M
Ovid Therapeutics operating income in 2021 was $124.21M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Operating Income
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation